Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Elagolix in Women With Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be female, aged 18 to 49 years, inclusive.~* Have moderate to severe pelvic pain due to endometriosis.~* Have a history of regular menstrual cycles.~* Have been surgically (laparoscopy or laparotomy) diagnosed with endometriosis within 8 years of the start of screening.~* Have a Body Mass Index (BMI) of 18 to 36 kg/m², inclusive.~* Agree to use two forms of non-hormonal contraception during the study.~Exclusion Criteria:~* Are currently receiving gonadotropin-releasing hormone (GnRH) agonist, a GnRH antagonist other than NBI-56418, or danazol or have received any of these agents within 6 months of the start of screening.~* Are currently receiving subcutaneous medroxyprogesterone acetate (DMPA-SC) or intramuscular medroxyprogesterone acetate (DMPA-IM) or have received any of these agents within 3 months of the start of screening.~* Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month.~* Have had surgery for endometriosis within the last month.~* Have had a hysterectomy or bilateral oophorectomy.~* Are using systemic steroids on a chronic or regular basis within 3 months.~* Have uterine fibroids ≥ 3 cm in diameter.~* Have pelvic pain that is not caused by endometriosis.~* Have unstable medical condition or chronic disease.~* Have been pregnant within the last six months.~* Currently breast feeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Elagolix 150 mg (Type: EXPERIMENTAL): Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).